One year ago, Congress defunded public media. Now that we're 100% community funded, please become a sustaining member or increase your existing membership today.
This archival content was originally written for and published on KPCC.org. Keep in mind that links and images may no longer work — and references may be outdated.
FDA approves clinical trials for new stem cell therapy for heart attack patients
A scientist holds a tray of stem cells.
(
Spencer Platt/Getty Images
)
Listen
0:52
FDA approves clinical trials for new stem cell therapy for heart attack patients
Federal authorities have given the go-ahead to human trials that will use a new stem cell treatment to repair heart attack damage.
Researchers at Cedars-Sinai in Los Angeles led the study into this new stem-cell-based treatment that helps to repair damage that cardiac arrest inflicts on heart muscle.
While preliminary therapies derived from a patient’s own cells have shown to reduce heart attack scarring, this new therapy would treat victims with human stem cells that are mass-replicated in a lab.
Research into the new therapy was supported by a $5.5 million grant from CIRM — the California stem cell agency that was created by voter-approved Proposition 71. This success marks the first time research by a CIRM-funded disease team has resulted in the FDA approving a potential new drug for clinical trials in humans.
Researchers say that, if it’s ultimately approved by the FDA, the new therapy could help the hundreds of thousands of Americans who each year have heart attacks.
The Los Angeles-based biotech firm, Capricor, will be leading the clinical trials.
One year ago, Congress voted to defund public media, eliminating a critical $1.7 million from our budget every year going forward. But they couldn’t silence us, and we’re not going anywhere. LAist is now 100% community funded and that means we’re taking our future into our own hands and turning to you to keep local reporting strong.
You come to LAist because you want independent reporting and trustworthy local information. Our nonprofit newsroom doesn’t answer to shareholders looking to turn a profit. Instead, we answer to you and our communities. We are free to follow facts wherever they lead and to hold power to account without fear or favor. Our only loyalty is to our readers and listeners and our mission: to inform, engage, and strengthen Southern California’s communities.
If this story helped you, please become a monthly member today to help sustain this mission. It just takes 1 minute to donate below.
You come to LAist because you want independent reporting and trustworthy local information. Our nonprofit newsroom doesn’t answer to shareholders looking to turn a profit. Instead, we answer to you and our communities. We are free to follow facts wherever they lead and to hold power to account without fear or favor. Our only loyalty is to our readers and listeners and our mission: to inform, engage, and strengthen Southern California’s communities.
If this story helped you, please become a monthly member today to help sustain this mission. It just takes 1 minute to donate below.
Senior Vice President News, Editor in Chief
